Innovative Research Award
Mehmet Kızılkaya
Trabzon Kanuni Training and Research Hospital, Turkey
Mehmet Kızılkaya is a researcher affiliated with Trabzon Kanuni Training and Research Hospital in Turkey, working within the broad field of Medicine and Health Sciences. The available publication record identifies a 2026 research contribution concerning prognostic indicators in older patients with prostate cancer undergoing definitive radiotherapy. The documented work examines myopenia, myosteatosis, and frailty as clinically relevant characteristics in this patient population. [1]
Abstract
This academic recognition profile presents the available research record associated with Mehmet Kızılkaya. The documented publication addresses the prognostic significance of myopenia, myosteatosis, and frailty among older patients with prostate cancer receiving definitive radiotherapy. These variables represent aspects of muscle quantity, muscle quality, and overall vulnerability that may contribute to the clinical characterization of older oncology patients. The publication appeared in Cancer Control in 2026 and lists Kızılkaya among its authors. [1]
Keywords
- Prostate cancer
- Radiotherapy
- Myopenia
- Frailty
- Geriatric oncology
Introduction
Age-associated changes in muscle mass, muscle composition, and functional reserve are increasingly considered in the assessment of older adults with cancer. In prostate cancer, definitive radiotherapy is an established treatment approach, while patient-level characteristics can influence prognosis and treatment planning. The reported study focuses specifically on myopenia, myosteatosis, and frailty, providing a clinical research perspective on these factors in older patients receiving radiotherapy. [1]
Research Profile
The available bibliographic information records one research document and one citation, with an h-index of 1 in the supplied profile data. The documented publication is situated within Medicine and Health Sciences and concerns an interdisciplinary clinical question connecting oncology, radiotherapy, geriatric assessment, and body-composition-related prognostic factors. Because only a limited set of bibliometric information is available, broader measures of research productivity and longitudinal impact should be interpreted cautiously.
Research Contributions
Kızılkaya’s documented contribution is part of a multi-author investigation of prognostic characteristics in older patients with prostate cancer. The study’s focus on myopenia, myosteatosis, and frailty contributes to a research framework in which conventional cancer outcomes can be considered alongside patient-specific physical characteristics. The work also illustrates collaboration across clinical disciplines involved in cancer management and radiotherapy. [1]
Publications
Prognostic Significance of Myopenia, Myosteatosis, and Frailty in Older Patients With Prostate Cancer Undergoing Definitive Radiotherapy — RA Aksoy, T Koca, DA Çetmi, M Kızılkaya, and AF Korcum. Published in Cancer Control, volume 33, in 2026. The available record reports article identifier 10732748261446040 and one citation. [1]
Research Impact
The available citation record documents an early bibliometric impact for the reported publication. With one document and one citation in the supplied data, quantitative indicators remain limited and should not be interpreted as a comprehensive measure of scholarly influence. The clinical relevance of the research can instead be understood through its focus on prognostic assessment in an older prostate-cancer population and its integration of muscle-related and frailty-related characteristics. [1]
Award Suitability
For the Innovative Research Award associated with the Global Innovation Technologist Awards, the documented research provides identifiable evidence of participation in contemporary clinical research involving prostate cancer, definitive radiotherapy, and prognostic characteristics of older patients. Relevant considerations include the specificity of the research question, its multidisciplinary clinical context, and the publication record available for verification. A complete award assessment would require the relevant official profile identifiers and any additional documented research outputs supplied for evaluation.
Conclusion
The available record identifies Mehmet Kızılkaya as a contributor to research examining myopenia, myosteatosis, and frailty in older patients with prostate cancer undergoing definitive radiotherapy. The publication establishes a clear connection with Medicine and Health Sciences and provides a documented basis for recognizing research activity in clinical oncology. Additional publications, identifiers, citations, and longitudinal metrics would allow a more comprehensive assessment of the research profile.
External Links
References
- Aksoy, R. A., Koca, T., Çetmi, D. A., Kızılkaya, M., & Korcum, A. F. (2026). Prognostic Significance of Myopenia, Myosteatosis, and Frailty in Older Patients With Prostate Cancer Undergoing Definitive Radiotherapy.
https://journals.sagepub.com/doi/full/10.1177/10732748261446040
- Cancer Control. (2026). Bibliographic record for the reported prostate cancer radiotherapy research article.
- Google Scholar. (2026). Citation record associated with the reported publication.
- Global Innovation Technologist Awards. (n.d.). Official awards website.
innovationtechnologist.com
- SAGE Journals. (n.d.). Cancer Control: Journal information and publication platform.